Overview

rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics

Status:
Unknown status

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The study is a single center and open test, and the dose of successive incremental method was taken. In order to determine the tolerance and safety after a single intravenous injection of different doses of rESP in healthy subjects, the investigators had this trial. On the other hand, this study is to preliminarily explore the pharmacokinetics in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Shenyang Sunshine Pharmaceutical Co., LTD.

Treatments:

Epoetin Alfa